Working… Menu

ANAVEX2-73 for Treatment of Early Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03790709
Recruitment Status : Recruiting
First Posted : January 2, 2019
Last Update Posted : April 30, 2021
Anavex Australia Pty Ltd.
Anavex Germany GmbH
Anavex Canada Ltd.
Information provided by (Responsible Party):
Anavex Life Sciences Corp.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 30, 2022
Estimated Study Completion Date : June 30, 2022